Structured Review

Novartis antibody expression
Antibody Expression, supplied by Novartis, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody expression/product/Novartis
Average 89 stars, based on 1 article reviews
Price from $9.99 to $1999.99
antibody expression - by Bioz Stars, 2020-09
89/100 stars

Images

Related Articles

Functional Assay:

Article Title: Design of therapeutic proteins with enhanced stability
Article Snippet: .. We thank Dr. Holger Heine from Novartis for his expert advice and help with setting up the antibody expression and purification systems; Dr. Burkhard Wilms from Novartis for providing the DNA vectors for antibody A and antibody B; Drs. Christoph Baechler, Thomas Millward, and Hans-Joachim Wallny from Novartis for performing functional analysis of our variants; Dr. Jean-Michel Rondeau from Novartis for providing X-ray structures of the Fab and Fc fragments of antibody A; and Prof. Dane Wittrup (MIT, Cambridge, MA) for helpful discussions and for use of laboratory equipment. ..

Expressing:

Article Title: Design of therapeutic proteins with enhanced stability
Article Snippet: .. We thank Dr. Holger Heine from Novartis for his expert advice and help with setting up the antibody expression and purification systems; Dr. Burkhard Wilms from Novartis for providing the DNA vectors for antibody A and antibody B; Drs. Christoph Baechler, Thomas Millward, and Hans-Joachim Wallny from Novartis for performing functional analysis of our variants; Dr. Jean-Michel Rondeau from Novartis for providing X-ray structures of the Fab and Fc fragments of antibody A; and Prof. Dane Wittrup (MIT, Cambridge, MA) for helpful discussions and for use of laboratory equipment. ..

Purification:

Article Title: Design of therapeutic proteins with enhanced stability
Article Snippet: .. We thank Dr. Holger Heine from Novartis for his expert advice and help with setting up the antibody expression and purification systems; Dr. Burkhard Wilms from Novartis for providing the DNA vectors for antibody A and antibody B; Drs. Christoph Baechler, Thomas Millward, and Hans-Joachim Wallny from Novartis for performing functional analysis of our variants; Dr. Jean-Michel Rondeau from Novartis for providing X-ray structures of the Fab and Fc fragments of antibody A; and Prof. Dane Wittrup (MIT, Cambridge, MA) for helpful discussions and for use of laboratory equipment. ..

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Novartis egfr differential expression
    Inverse correlation of <t>EGFR</t> and PCNA expression are found in LUAD, <t>COAD,</t> and cell lines from multiple tumor types (Cancer Cell Line Encyclopedia; (CCLE); n = 877; Supplementary Table 2) but not in glioblastoma (GBB) or breast cancer (BRCA). ( A ) EGFR ( blue ) and PCNA ( min-max ) curve ( grey ); LUAD, COAD, CCLE cell lines, GBB, and BRCA. ( B ) EGFR overexpression accompanies secondary gene overexpression that can vary proportionally with proliferation. EGFR ( magenta ), CLPTM1L ( blue ) cases arranged by EGFR expression ( min-max ) illustrating direct proportion; EGFR ( magenta ) CLPTM1L ( blue ) and PCNA ( grey ) cases rearranged by PCNA expression ( min-max ) illustrating indirect proportion to proliferation. EGFR ( magenta ), VOPP1 ( blue ) arranged by EGFR expression ( min-max ); EGFR ( magenta ), VOPP1 ( blue ), and PCNA ( grey ) cases rearranged by PCNA expression ( min-max ) illustrating simultaneous VOPP1 direct proportion and EGFR indirect proportion to proliferation. URGCP ( pink ), KLHL7 ( orange ), YKT6 ( green ), POLD2 ( purple ), FAM220A ( magenta ), all arranged by PCNA expression ( min-max ) ( grey ).
    Egfr Differential Expression, supplied by Novartis, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr differential expression/product/Novartis
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr differential expression - by Bioz Stars, 2020-09
    93/100 stars
      Buy from Supplier

    85
    Novartis autoreactive b cells
    Defective receptor editing induction in IRAK-4- and MyD88-deficient developing <t>autoreactive</t> B cells
    Autoreactive B Cells, supplied by Novartis, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/autoreactive b cells/product/Novartis
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    autoreactive b cells - by Bioz Stars, 2020-09
    85/100 stars
      Buy from Supplier

    88
    Novartis igf 1r expression
    <t>IGF-1R</t> expression in GIST biopsies
    Igf 1r Expression, supplied by Novartis, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf 1r expression/product/Novartis
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    igf 1r expression - by Bioz Stars, 2020-09
    88/100 stars
      Buy from Supplier

    85
    Novartis bcr abl expressing leukemia cells
    WP1130 reduces the viability of cells expressing wild-type and mutant <t>Bcr/Abl</t> . (A) BaF/3 cells (1 × 10 4 ) expressing wild-type or mutant Bcr/Abl (T315I, L364I, E355G) were treated with the indicated concentration of WP1130 or <t>imatinib</t> mesylate
    Bcr Abl Expressing Leukemia Cells, supplied by Novartis, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl expressing leukemia cells/product/Novartis
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl expressing leukemia cells - by Bioz Stars, 2020-09
    85/100 stars
      Buy from Supplier

    Image Search Results


    Inverse correlation of EGFR and PCNA expression are found in LUAD, COAD, and cell lines from multiple tumor types (Cancer Cell Line Encyclopedia; (CCLE); n = 877; Supplementary Table 2) but not in glioblastoma (GBB) or breast cancer (BRCA). ( A ) EGFR ( blue ) and PCNA ( min-max ) curve ( grey ); LUAD, COAD, CCLE cell lines, GBB, and BRCA. ( B ) EGFR overexpression accompanies secondary gene overexpression that can vary proportionally with proliferation. EGFR ( magenta ), CLPTM1L ( blue ) cases arranged by EGFR expression ( min-max ) illustrating direct proportion; EGFR ( magenta ) CLPTM1L ( blue ) and PCNA ( grey ) cases rearranged by PCNA expression ( min-max ) illustrating indirect proportion to proliferation. EGFR ( magenta ), VOPP1 ( blue ) arranged by EGFR expression ( min-max ); EGFR ( magenta ), VOPP1 ( blue ), and PCNA ( grey ) cases rearranged by PCNA expression ( min-max ) illustrating simultaneous VOPP1 direct proportion and EGFR indirect proportion to proliferation. URGCP ( pink ), KLHL7 ( orange ), YKT6 ( green ), POLD2 ( purple ), FAM220A ( magenta ), all arranged by PCNA expression ( min-max ) ( grey ).

    Journal: Oncotarget

    Article Title: Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation

    doi: 10.18632/oncotarget.27316

    Figure Lengend Snippet: Inverse correlation of EGFR and PCNA expression are found in LUAD, COAD, and cell lines from multiple tumor types (Cancer Cell Line Encyclopedia; (CCLE); n = 877; Supplementary Table 2) but not in glioblastoma (GBB) or breast cancer (BRCA). ( A ) EGFR ( blue ) and PCNA ( min-max ) curve ( grey ); LUAD, COAD, CCLE cell lines, GBB, and BRCA. ( B ) EGFR overexpression accompanies secondary gene overexpression that can vary proportionally with proliferation. EGFR ( magenta ), CLPTM1L ( blue ) cases arranged by EGFR expression ( min-max ) illustrating direct proportion; EGFR ( magenta ) CLPTM1L ( blue ) and PCNA ( grey ) cases rearranged by PCNA expression ( min-max ) illustrating indirect proportion to proliferation. EGFR ( magenta ), VOPP1 ( blue ) arranged by EGFR expression ( min-max ); EGFR ( magenta ), VOPP1 ( blue ), and PCNA ( grey ) cases rearranged by PCNA expression ( min-max ) illustrating simultaneous VOPP1 direct proportion and EGFR indirect proportion to proliferation. URGCP ( pink ), KLHL7 ( orange ), YKT6 ( green ), POLD2 ( purple ), FAM220A ( magenta ), all arranged by PCNA expression ( min-max ) ( grey ).

    Article Snippet: Examining the behavior of EGFR differential expression to proliferation markers in COAD, BRCA, GBB, and the Cancer Cell Line Encyclopedia (from the Broad Institute and Novartis, 877 samples) [ , ] (Supplementary Table 2) permitted identification of the inverse relationship in COAD and in the cell lines, but not in GBB or BRCA ( ).

    Techniques: Expressing, Over Expression

    Defective receptor editing induction in IRAK-4- and MyD88-deficient developing autoreactive B cells

    Journal:

    Article Title: IRAK-4/MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans

    doi: 10.1016/j.immuni.2008.09.015

    Figure Lengend Snippet: Defective receptor editing induction in IRAK-4- and MyD88-deficient developing autoreactive B cells

    Article Snippet: Since the genes encoding IL-1R1, IL-18R1, and IL-1RL1 are not expressed in control new emigrant and mature naïve B cells, these molecules are not likely to play a direct role in the removal of developing autoreactive B cells ( , and Genomics Institute of the Novartis Research Foundation expression anatomy database).

    Techniques:

    IGF-1R expression in GIST biopsies

    Journal:

    Article Title: The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors

    doi:

    Figure Lengend Snippet: IGF-1R expression in GIST biopsies

    Article Snippet: With respect to IGF-1R expression and its contribution to downstream signaling pathways, we showed that the small molecule tyrosine kinase inhibitor NVP-AEW541 (Novartis), which has activity against IGF-1R , decreases ligand-stimulated IGF-1R auto-phosphorylation in the GIST cell lines T1 and 882 without affecting phospho-KIT levels, and furthermore decreases the phosphorylation of downstream signaling molecules AKT, MAPK1/2 and GSKβ.

    Techniques: Expressing

    WP1130 reduces the viability of cells expressing wild-type and mutant Bcr/Abl . (A) BaF/3 cells (1 × 10 4 ) expressing wild-type or mutant Bcr/Abl (T315I, L364I, E355G) were treated with the indicated concentration of WP1130 or imatinib mesylate

    Journal:

    Article Title: Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

    doi: 10.1182/blood-2006-02-005579

    Figure Lengend Snippet: WP1130 reduces the viability of cells expressing wild-type and mutant Bcr/Abl . (A) BaF/3 cells (1 × 10 4 ) expressing wild-type or mutant Bcr/Abl (T315I, L364I, E355G) were treated with the indicated concentration of WP1130 or imatinib mesylate

    Article Snippet: – Previous studies showed that reducing intracellular levels of Bcr/Abl mRNA or protein led to inhibition of proliferation and clonogenic survival of Bcr/Abl-expressing leukemia cells., The introduction of imatinib mesylate (Gleevec; STI-571; CGP57148B; Novartis, East Hanover, NJ) revolutionized the treatment of CML, because it selectively inhibits the kinase activity of Bcr/Abl without adversely affecting normal cells.

    Techniques: Expressing, Mutagenesis, Concentration Assay